161 related articles for article (PubMed ID: 35144966)
1. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga RC; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Clin Cancer Res; 2022 May; 28(9):1871-1880. PubMed ID: 35144966
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
4. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
[TBL] [Abstract][Full Text] [Related]
5. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Mamounas EP; Bandos H; Rastogi P; Zhang Y; Treuner K; Lucas PC; Geyer CE; Fehrenbacher L; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil S; Paik S; Swain SM; Sgroi DC; Schnabel CA; Wolmark N
Clin Cancer Res; 2024 May; 30(9):1984-1991. PubMed ID: 38376912
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Jankowitz RC; Cooper K; Erlander MG; Ma XJ; Kesty NC; Li H; Chivukula M; Brufsky A
Breast Cancer Res; 2011 Oct; 13(5):R98. PubMed ID: 21999244
[TBL] [Abstract][Full Text] [Related]
9. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Sgroi DC; Chapman JA; Badovinac-Crnjevic T; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Shepherd LE; Goss PE; Pollak M
Breast Cancer Res; 2016 Jan; 18(1):1. PubMed ID: 26728744
[TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
13. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L;
Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227
[TBL] [Abstract][Full Text] [Related]
14. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
15. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
17. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW;
Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403
[TBL] [Abstract][Full Text] [Related]
18. Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.
Roseweir AK; Bennett L; Dickson A; Cheng K; Quintayo MA; Bayani J; McMillan DC; Horgan PG; van de Velde CJH; Seynaeve C; Hasenburg A; Kieback DG; Markopoulos C; Dirix LY; Rea DW; Mallon EA; Bartlett JMS; Edwards J
J Natl Cancer Inst; 2018 Jun; 110(6):616-627. PubMed ID: 29917140
[TBL] [Abstract][Full Text] [Related]
19. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
20. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
